These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 10877724)

  • 1. Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin.
    Bottorff M
    Am J Cardiol; 2000 Apr; 85(8):1042-3. PubMed ID: 10877724
    [No Abstract]   [Full Text] [Related]  

  • 2. Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin.
    Gruer PJ; Vega JM; Mercuri MF; Dobrinska MR; Tobert JA
    Am J Cardiol; 1999 Oct; 84(7):811-5. PubMed ID: 10513779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations.
    Kantola T; Kivistö KT; Neuvonen PJ
    Clin Pharmacol Ther; 1998 Aug; 64(2):177-82. PubMed ID: 9728898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rhabdomyolysis after concomitant use of cyclosporine, simvastatin, gemfibrozil, and itraconazole.
    Maxa JL; Melton LB; Ogu CC; Sills MN; Limanni A
    Ann Pharmacother; 2002 May; 36(5):820-3. PubMed ID: 11978159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-administration of statins with cytochrome P450 3A4 inhibitors in a UK primary care population.
    Bakhai A; Rigney U; Hollis S; Emmas C
    Pharmacoepidemiol Drug Saf; 2012 May; 21(5):485-93. PubMed ID: 22237927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rhabdomyolysis due to probable interaction between simvastatin and ritonavir.
    Cheng CH; Miller C; Lowe C; Pearson VE
    Am J Health Syst Pharm; 2002 Apr; 59(8):728-30. PubMed ID: 11977859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of concomitant treatment with a CYP3A4 inhibitor and a calcium channel blocker.
    Yoshida M; Matsumoto T; Suzuki T; Kitamura S; Mayama T
    Pharmacoepidemiol Drug Saf; 2008 Jan; 17(1):70-5. PubMed ID: 17918187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simvastatin prescribing patterns before and after FDA dosing restrictions: a retrospective analysis of a large healthcare claims database.
    Tuchscherer RM; Nair K; Ghushchyan V; Saseen JJ
    Am J Cardiovasc Drugs; 2015 Feb; 15(1):27-34. PubMed ID: 25348907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A neural network based virtual screening of cytochrome P450 3A4 inhibitors.
    Molnar L; Keseru GM
    Bioorg Med Chem Lett; 2002 Feb; 12(3):419-21. PubMed ID: 11814811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole.
    Neuvonen PJ; Kantola T; Kivistö KT
    Clin Pharmacol Ther; 1998 Mar; 63(3):332-41. PubMed ID: 9542477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism-based inactivation of cytochrome P450 3A4 by 17 alpha-ethynylestradiol: evidence for heme destruction and covalent binding to protein.
    Lin HL; Kent UM; Hollenberg PF
    J Pharmacol Exp Ther; 2002 Apr; 301(1):160-7. PubMed ID: 11907170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simvastatin-diltiazem drug interaction resulting in rhabdomyolysis and hepatitis.
    Kanathur N; Mathai MG; Byrd RP; Fields CL; Roy TM
    Tenn Med; 2001 Sep; 94(9):339-41. PubMed ID: 11550401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rhabdomyolysis due to interaction of simvastatin with mibefradil.
    Schmassmann-Suhijar D; Bullingham R; Gasser R; Schmutz J; Haefeli WE
    Lancet; 1998 Jun; 351(9120):1929-30. PubMed ID: 9654265
    [No Abstract]   [Full Text] [Related]  

  • 14. Human reductive halothane metabolism in vitro is catalyzed by cytochrome P450 2A6 and 3A4.
    Spracklin DK; Thummel KE; Kharasch ED
    Drug Metab Dispos; 1996 Sep; 24(9):976-83. PubMed ID: 8886607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Avoiding patient morbidity: Updated statin drug interactions and risks for patient harm.
    Finks SW; Campbell JD
    Nurse Pract; 2014 Nov; 39(11):45-51. PubMed ID: 25325525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elucidation of distinct ligand binding sites for cytochrome P450 3A4.
    Hosea NA; Miller GP; Guengerich FP
    Biochemistry; 2000 May; 39(20):5929-39. PubMed ID: 10821664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The licorice root derived isoflavan glabridin inhibits the activities of human cytochrome P450S 3A4, 2B6, and 2C9.
    Kent UM; Aviram M; Rosenblat M; Hollenberg PF
    Drug Metab Dispos; 2002 Jun; 30(6):709-15. PubMed ID: 12019199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiprogestin-mediated inactivation of cytochrome P450 3A4.
    Jang GR; Benet LZ
    Pharmacology; 1998 Mar; 56(3):150-7. PubMed ID: 9532615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates.
    Stresser DM; Blanchard AP; Turner SD; Erve JC; Dandeneau AA; Miller VP; Crespi CL
    Drug Metab Dispos; 2000 Dec; 28(12):1440-8. PubMed ID: 11095581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does differing metabolism by cytochrome p450 have clinical importance?
    Davidson MH
    Curr Atheroscler Rep; 2000 Jan; 2(1):14-9. PubMed ID: 11122720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.